Postpartum depression patients, major depressive disorder patients, and healthy postpartum women. Mental and Behavioural Disorders
Conditions
Interventions
This study will be conducted across two centers to investigate the differences in glutamate metabolism among women with postpartum depression (PPD), major depressive disorder (MDD), and healthy postpa
Sponsors
National Natural Science Foundation of China
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. They meet the diagnostic criteria for postpartum depression or major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), or they are healthy postpartum women. 2. They are females aged between 18 and 49 years. 3. They have signed the informed consent form and voluntarily agree to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Pregnant women. 2. Alcohol dependence or dependence on addictive drugs. 3. Suicidal tendencies, with suicidal behavior within the past year. 4. Received antidepressant medication treatment within one month prior to the trial. 5. History of or current bipolar disorder, schizophrenia, organic brain disease, intellectual disability, or antisocial personality disorder. 6. Contraindications to electroacupuncture, such as severe heart disease (e.g., having a pacemaker), severe coagulation dysfunction, or skin damage and ulcers at the acupuncture sites.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate after treatment. Definition of efficacy (Response): A reduction rate of = 50% in the score of the 17-item Hamilton Depression Rating Scale (HAMD-17) before and after treatment is defined as effective (Response). Calculation formula for reduction rate: (Pre-treatment HAMD-17 score - Post-treatment HAMD-17 score)/Pre-treatment HAMD-17 score × 100%. | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 23/04/2025: The following secondary outcome measures are assessed at pre-treatment and post-treatment: 1. Depression severity is measured using the Hamilton Depression Rating Scale, 17-item (HAMD-17) 2. Anxiety severity is measured using the Hamilton Anxiety Scale (HAMA) 3. Sleep patterns of women during the postpartum period measured using the Postpartum Sleep Quality Scale (PSQS) and the Pittsburgh Sleep Quality Index (PSQI) scale 4. Glutamate metabolism levels are measured in tongue coating and feces using 16S rRNA gene sequencing and metaproteomic analysis, in serum using enzyme-linked immunosorbent assay (ELISA), in plasma using ELISA, high-performance liquid chromatography, and targeted mass spectrometry, and in PBMCs using quantitative polymerase chain reaction Previous secondary outcome measures: 1. Depression severity is measured using the Hamilton Depression Rating Scale, 17-item (HAMD-17) at pre-treatment and post-treatment 2. Self-rated depression severity is measured using the Self-Rating Depression Scale (SDS) at pre-treatment and post-treatment 3. Anxiety severity is measured using the Hamilton Anxiety Scale (HAMA) at pre-treatment and post-treatment 4. Self-rated sleep quality is measured using the Self-Rating Scale of Sleep (SRSS) at pre-treatment and post-treatment 5. Glutamate metabolism levels are measured using tongue coating, feces, serum, plasma, and PBMC at pre-treatment and post-treatment | — |
Countries
China
Contacts
Public ContactHong Zhao
Outcome results
None listed